Bermann PE. Aging skin: causes, treatments, and prevention. Nurs Clin North Am. 2007;42(3):485–500. https://doi.org/10.1016/j.cnur.2007.05.001.
Baumann L. Skin ageing and its treatment. J Pathol. 2007;211(2):241–51. https://doi.org/10.1002/path.2098.
Article CAS PubMed Google Scholar
Kopera D. Botulinum toxin historical aspects: from food poisoning to pharmaceutical. Int J Dermatol. 2011;50(8):976–80. https://doi.org/10.1111/j.1365-4632.2010.04821.
Article CAS PubMed Google Scholar
Carruthers J, Carruthers A. The evolution of botulinum neurotoxin type a for cosmetic applications. J Cosmet Laser Ther. 2007;9(3):186–92. https://doi.org/10.1080/14764170701411470.
De Boulle K, Fagien S, Sommer B, Glogau R. Treating glabellar lines with botulinum toxin type A-hemagglutinin complex: a review of the science, the clinical data, and patient satisfaction. Clin Interv Aging. 2010;5:101. https://doi.org/10.2147/cia.s9338.
Article PubMed PubMed Central Google Scholar
Wheeler A, Smith HS. Botulinum toxins: mechanisms of action, antinociception and clinical applications. Toxicology. 2013;306:124–46. https://doi.org/10.1016/j.tox.2013.02.006.
Article CAS PubMed Google Scholar
Stone HF, Zhu Z, Thach TQ, Ruegg CL. Characterization of diffusion and duration of action of a new botulinum toxin type a formulation. Toxicon. 2011;58(2):159–67.
Article CAS PubMed Google Scholar
Giordano CN, Matarasso SL, Ozog DM. Injectable and topical neurotoxins in dermatology: basic science, anatomy, and therapeutic agents. J Am Acad Dermatol. 2017;76(6):1013–24. https://doi.org/10.1016/j.jaad.2016.11.012.
Article CAS PubMed Google Scholar
Deshayes S, Morris M, Divita G, Heitz F. Cell-penetrating peptides: tools for intracellular delivery of therapeutics. Cell Mol Life Sci. 2005;62(16):1839–49. https://doi.org/10.1007/s00018-005-5109-0.
Article CAS PubMed Google Scholar
Järver P, Langel Ü. Cell-penetrating peptides—a brief introduction. Bba-Biomembranes. 2006;3(1758):260–3. https://doi.org/10.1016/j.bbamem.2006.02.012.
Bechara C, Pallerla M, Zaltsman Y, Burlina F, Alves ID, Lequin O, Sagan S. Tryptophan within basic peptide sequences triggers glycosaminoglycan-dependent endocytosis. FASEB J. 2013;27(2):738–49. https://doi.org/10.1096/fj.12-216176.
Article CAS PubMed Google Scholar
Langel Ü. Cell-penetrating peptides. Springer; 2011.
Zorko M, Langel Ü. Cell-penetrating peptides: mechanism and kinetics of cargo delivery. Adv Drug Deliv Rev. 2005;57(4):529–45. https://doi.org/10.1016/j.addr.2004.10.010.
Article CAS PubMed Google Scholar
Patel LN, Zaro JL, Shen W-C. Cell penetrating peptides: intracellular pathways and pharmaceutical perspectives. Pharm Res. 2007;24(11):1977–92. https://doi.org/10.1007/s11095-007-9303-7.
Article CAS PubMed Google Scholar
Bechara C, Sagan S. Cell-penetrating peptides: 20 years later, where do we stand? FEBS Lett. 2013;587(12):1693–702. https://doi.org/10.1016/j.febslet.2013.04.031.
Article CAS PubMed Google Scholar
Morris MC, Depollier J, Mery J, Heitz F, Divita G. A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat Biotechnol. 2001;19(12):1173–6. https://doi.org/10.1038/nbt1201-1173.
Article CAS PubMed Google Scholar
Manoochehri S, Darvishi B, Kamalinia G, Amini M, Fallah M, Ostad SN, Atyabi F, Dinarvand R. Surface modification of PLGA nanoparticles via human serum albumin conjugation for controlled delivery of docetaxel. DARU J Pharm Sci. 2013;21(1):1–10. https://doi.org/10.1186/2008-2231-21-58.
Lee JY, Choi YS, Suh JS, Kwon YM, Yang VC, Lee SJ, Chung CP, Park YJ. Cell-penetrating chitosan/doxorubicin/TAT conjugates for efficient cancer therapy. Int J Cancer. 2011;128(10):2470–80. https://doi.org/10.1002/ijc.25578.
Article CAS PubMed Google Scholar
Broide RS, Rubino J, Nicholson GS, Ardila MC, Brown MS, Aoki KR, Francis J. The rat digit abduction score (DAS) assay: a physiological model for assessing botulinum neurotoxin-induced skeletal muscle paralysis. Toxicon. 2013;71:18–24. https://doi.org/10.1016/j.toxicon.2013.05.004.
Article CAS PubMed Google Scholar
Bonventre P, Kempe L. Physiology of toxin production by clostridium botulinum types a and B: III. Effect of pH and temperature during incubation on growth, autolysis, and toxin production. Appl Microbiol. 1959;7(6):374–7. https://doi.org/10.1128/jb.79.1.18-23.1960.
Article CAS PubMed PubMed Central Google Scholar
Pirazzini M, Rossetto O, Eleopra R, Montecucco C. Botulinum neurotoxins: biology, pharmacology, and toxicology. Pharmacol Rev. 2017;69(2):200–35. https://doi.org/10.1124/pr.116.012658.
Article CAS PubMed PubMed Central Google Scholar
Shi N-Q, Qi X-R, Xiang B, Zhang Y. A survey on “Trojan horse” peptides: opportunities, issues and controlled entry to “Troy”. J Control Release. 2014;194:53–70. https://doi.org/10.1016/j.jconrel.2014.08.014.
Article CAS PubMed Google Scholar
Drugs@FDA: FDA-Approved Drugs. [cited 2022 10-8]; Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process.
Drug Approval Package: DAXXIFY. [cited 2022 10-08]; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/761127Orig1s000TOC.cfm.
Brock R. The uptake of arginine-rich cell-penetrating peptides: putting the puzzle together. Bioconjug Chem. 2014;25(5):863–8. https://doi.org/10.1021/bc500017t.
Article CAS PubMed Google Scholar
Vives E, Brodin P, Lebleu B. A truncated HIV-1 tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem. 1997;272(25):16010–7. https://doi.org/10.1074/jbc.272.25.16010.
Article CAS PubMed Google Scholar
Ben David A, Diamant E, Barnea A, Rosen O, Torgeman A, Zichel R. The receptor binding domain of botulinum neurotoxin serotype a (BoNT/a) inhibits BoNT/a and BoNT/E intoxications in vivo. Clin Vaccine Immunol. 2013;20(8):1266–73. https://doi.org/10.1128/CVI.00268-13.
Article CAS PubMed PubMed Central Google Scholar
Saffarian P, Peerayeh SN, Amani J, Ebrahimi F, Sedighian H, Halabian R, Fooladi AAI. TAT-BoNT/a (1–448), a novel fusion protein as a therapeutic agent: analysis of transcutaneous delivery and enzyme activity. Appl Microbiol Biotechnol. 2016;100(6):2785–95. https://doi.org/10.1007/s00253-015-7240-7.
Article CAS PubMed Google Scholar
Kim D-W, Kim S-Y, An J-J, Lee S-H, Jang S-H, Won M-H, Kang T-C, Chung K-H, Jung H-H, Cho S-W. Expression, purification and transduction of PEP-1-botulinum neurotoxin type a (PEP-1-BoNT/a) into skin. BMB Rep. 2006;39(5):642–7. https://doi.org/10.5483/bmbrep.2006.39.5.642.
Ahmad Nasrollahi S, Taghibiglou C, Fouladdel S, Dinarvand R, Moosavi Movahedi AA, Azizi E, Farboud ES. Physicochemical and biological characterization of P ep-1/elastin complexes. Chem Biol Drug Des. 2013;82(2):189–95. https://doi.org/10.1111/cbdd.12150.
Article CAS PubMed Google Scholar
Mitchell DJ, Steinman L, Kim D, Fathman C, Rothbard J. Polyarginine enters cells more efficiently than other polycationic homopolymers. J Pept Res. 2000;56(5):318–25. https://doi.org/10.1034/j.1399-3011.2000.00723.
Article CAS PubMed Google Scholar
Ryser HJ-P, Hancock R. Histones and basic polyamino acids stimulate the uptake of albumin by tumor cells in culture. Science. 1965;150(3695):501–3. https://doi.org/10.1126/science.150.3695.501.
Article CAS PubMed Google Scholar
Lee J, Kennedy P, Waugh JM. Experiences with CPP-based self assembling peptide systems for topical delivery of botulinum toxin. In: Cell-penetrating peptides. Springer; 2015. p. 397–415.
Gros E, Deshayes S, Morris MC, Aldrian-Herrada G, Depollier J, Heitz F, Divita G. A non-covalent peptide-based strategy for protein and peptide nucleic acid transduction. Bba-Biomembranes. 2006;1758(3):384–93. https://doi.org/10.1016/j.bbamem.2006.02.006.
Article CAS PubMed Google Scholar
Waugh JM, Lee J, Dake MD, Browne D. Nonclinical and clinical experiences with CPP-based self-assembling peptide systems in topical drug development. Cell-penetrating. Peptides. 2011:553–72. https://doi.org/10.1007/978-1-60761-919-2_39.
Shabani Ravari N, Goodarzi N, Alvandifar F, Amini M, Souri E, Khoshayand MR, Hadavand Mirzaie Z, Atyabi F, Dinarvand R. Fabrication and biological evaluation of chitosan coated hyaluronic acid-docetaxel conjugate nanoparticles in CD44+ cancer cells. DARU Pharm Sci. 2016;24(1):1–12. https://doi.org/10.1186/s40199-016-0160.
留言 (0)